Metabonomics in Ulcerative Colitis: Diagnostics, Biomarker Identification, And Insight into the Pathophysiology

Citations Over TimeTop 10% of 2009 papers

Abstract

Nuclear magnetic resonance (NMR) spectroscopy and appropriate multivariate statistical analyses have been employed on mucosal colonic biopsies, colonocytes, lymphocytes, and urine from patients with ulcerative colitis (UC) and controls in order to explore the diagnostic possibilities, define new potential biomarkers, and generate a better understanding of the pathophysiology. Samples were collected from patients with active UC (n = 41), quiescent UC (n = 33), and from controls (n = 25) and analyzed by NMR spectroscopy. Data analysis was carried out by principal component analysis and orthogonal-projection to latent structure-discriminant analysis using the SIMCA P+11 software package (Umetrics, Umea, Sweden) and Matlab environment. Significant differences between controls and active UC were discovered in the metabolic profiles of biopsies and colonocytes. In the biopsies from patients with active UC higher levels of antioxidants and of a range of amino acids, but lower levels of lipid, glycerophosphocholine (GPC), myo-inositol, and betaine were found, whereas the colonocytes only displayed low levels of GPC, myo-inositol and choline. Interestingly, 20% of inactive UC patients had similar profiles to those who were in an active state. This study demonstrates the possibilities of metabonomics as a diagnostic tool in active and quiescent UC and provides new insight into pathophysiologic mechanisms.

Related Papers

• THE EXPERIMENTAL STUDY OF THE RELATED CYTOKINES FOR IN PATIENTS WITH ULCERATIVE COLITIS.(2005)
• Investigation of Serum NO Levels in Patients With Ulcerative Colitis(2002)
• Determination of plasma P-selection in patients with ulcerative colitis and their clinical significance(2004)
• The severity correlation of TNF-α,IL-6 and IL-8 levels in plasma in patients with ulcerative colitis and their clinical significances(2008)
• → To study on nutritional status in patients with ulcerative colitis(2023)